'Breakthrough' status granted to Aimmune's peanut allergy drug
The FDA has granted breakthrough therapy designation (BTD) to Aimmune Therapeutics' investigational oral immunotherapy for peanut allergy, known as AR101.
The FDA has granted breakthrough therapy designation (BTD) to Aimmune Therapeutics' investigational oral immunotherapy for peanut allergy, known as AR101.